Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis

Mod Rheumatol. 2016;26(3):465-6. doi: 10.3109/14397595.2015.1012797. Epub 2015 Jun 29.

Authors

Ryu Watanabe¹, Tomonori Ishii¹, Kyoko Araki¹, Mariko Ishizuka¹, Yukiko Kamogawa¹, Yoko Fujita¹, Yuko Shirota¹, Hiroshi Fujii¹, Hideo Harigae¹

Affiliation

¹ a Department of Hematology and Rheumatology , Tohoku University Graduate School of Medicine , Sendai , Japan.

PMID: 25698368
DOI: 10.3109/14397595.2015.1012797

No abstract available

Keywords: Clinically amyopathic dermatomyositis; Interstitial lung disease; Multi-target therapy; Rituximab.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adrenal Cortex Hormones / therapeutic use*
Cyclophosphamide / therapeutic use*
Dermatomyositis / complications*
Drug Therapy, Combination
Female
Humans
Immunosuppressive Agents / therapeutic use*
Lung Diseases, Interstitial / complications
Lung Diseases, Interstitial / drug therapy*
Middle Aged
Rituximab / therapeutic use*
Tacrolimus / therapeutic use*
Treatment Outcome

Substances

Adrenal Cortex Hormones
Immunosuppressive Agents
Rituximab
Cyclophosphamide
Tacrolimus

Supplementary concepts

Amyopathic dermatomyositis